PP212—Bioavailability of Digoxin Tablets, Low Therapeutic Index Drug, Determined by Emit  by Duda, J. et al.
Clinical Therapeutics
e84 Volume 35 Number 8S
Patients (or Materials) and Methods: The study was conducted in 12 
healthy volunteers. Each patient received a 1-g single dose intrave-
nously of sulbactam, after which PK studies were carried out, using 
a Monte Carlo simulation to determine the probability of attaining 
a specific pharmacodynamic target.
Results: The population PKs of sulbactam were; k12 = 0.637 (2.003) 
h-1, k21 = 0.663 (1.736) h-1, k13 = 8.626 (2.035) h-1, k31 = 5.424 
(2.058) h-1 ke = 3.223 (1.380) h-1, CL = 11.903 (1.978) L/h and V 
= 3.693 (1.434) L. The PTAs for selected regimens over a range of 
MICs were as follows:
Conclusion: The high PTA (≥ 90%) achieving 40% T> MIC for an 
MIC of 8 mg/L was observed when sulbactam was administered by a 
4-hour infusion of 3 g q8h, which would be an alternative treatment 
option for less-susceptible pathogens.
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Introduction: Piperine is the main pungent alkaloid present in the 
fruits of black pepper (Piper nigrum) and long pepper (Piper longum).
In traditional medicine, black pepper has been used as an analgesic 
and anti-inflammatory agent and in the treatment of epilepsy and 
snake venom poisoning. Piperine also has been reported as an inhibi-
tor against several cytochrome P-450–mediated pathways and Phase 
II metabolism as well as P-glycoprotein. This study was carried out 
to investigate the effect of piprine on the pharmacokinetics of dom-
peridone after acute and chronic administration in rats.
Patients (or Materials) and Methods: Animals received a single dose 
of domperidone (20 mg/kg, p.o.) alone or together with piperine (60 
mg/kg, p.o.). Similarly, the same doses of domperidone alone or when 
it was given together with piperine were administered to rats chroni-
cally for 5 days. Plasma samples were collected at 0.25, 0.5, 1.0, 2.0, 
3.0, 4.0, 6.0, 8.0, 10.0, and 12.0 hours after drug administration. 
The concentrations of domperidone in the plasma were measured 
using an HPLC method.
Results: The concomitant administration of piperine with dom-
peridone acutely or chronically resulted in a significant (P < 0.05) 
increase in the maximum plasma concentration (Cmax), the mean 
area under the plasma concentration–time curve (AUC), and the elim-
ination half-life (t½) of domperidone compared with those obtained 
for domperidone alone.
Conclusion: The concurrent administration of piprine with dom-
peridone to rats produced a significant increase in the plasma levels 
of the latter. However, further studies are needed to determine the 
possible mechanism(s) involved in this pharmacokinetic interaction.
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Introduction: Introducing of a standard drug monitoring for digoxin, 
a digitalis glycoside using in heart failure, considerably reduce the 
incidences of digoxin toxicity. The need for measurement of digoxin 
concentrations and knowledge about bioavailability of the given 
preparation arise from the low therapeutic index of digoxin and 
its concentration-dependent toxicity. The recommended therapeutic 
range (1.0–2.5 nmol/L) reflects significant increase in the risk of toxic-
ity that occurs with serum concentrations over 2.6 nmol/L. Choosing 
a proper analytical method for digoxin bioavailability evaluation is 
essential due to digoxin-like immunologic factor (DLIF) and others 
interfering substances that overestimate serum digoxin concentration 
which may be a significant clinical problem.
Patients (or Materials) and Methods: The study was performed on 
24 healthy volunteers in accordance with GCP and legal require-
ments. Digoxin tablets were administered as a single dose of 0.5 mg. 
Pharmacokinetic profiles were plotted up to 60 hours after dosing. 
Determination of digoxin concentration in serum samples was per-
formed by immunoenzymatic method by using the Emit® 2000 Digoxin 
Assay (Siemens Healthcare Diagnostics). EMIT is a homogeneous 
enzyme immunoassay intended for use in the quantitative analysis of 
digoxin in human serum or plasma. The method was fully validated 
according to the international guidelines. Original solutions of digoxin 
were used as calibration standards. Lower limit of quantification was 
set at the concentration of 0.1 ng/mL that is sufficient for human phar-
macokinetic evaluation. Standard pharmacokinetic and bioavailabil-
ity parameters in single-dose regiment (AUCt, AUCinf, Cmax, Tmax, 
MRT, t1/2) were calculated by a noncompartmental method.
Results: Study results, including t1/2 and other bioavailability 
parameters, were in agreement with the reference data. Mean AUCinf 
was 33.42 (10.13) ng*h/mL, while AUCt was 23.93 (6.70) ng*h/
mL. Cmax was observed as 3.24 (0.77) ng/mL but occurred at dif-
ferent Tmax (range, 0.5–2.5 hours). The intersubject variability was 
similar in case of AUC and Cmax (range, 23.80%–30.31%). The 
high variability of Tmax was observed (49.33%). Cmax exceed the 
recommended therapeutic ranges in most cases due to administration 
of a high dose of the tested drug. Digoxin tablets elimination half-life 
in healthy volunteers, even after single dose administration is high 
(32.78 [6.48] hours) as well as MRT (44.14 [8.34] hours).
Conclusion: The study results have confirmed that the EMIT method 
was appropriate for assessment digoxin bioavailability and can be 
used not only as reliable screening test but also in bioavailability and 
bioequivalence evaluation.
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Dosage regimen MIC (mg/L) PTA of T> MIC
20%
40% 30%
1 g q8h (1/2/3/4 h infusion) 1 0.17/0.99/0.99/0.99
2 0.00/0.21/0.99/0.99
4 0.00/0.00/0.44/0.99
2 g q8h (1/2/3/4 h infusion) 1 0.04/0.99/0.99/0.97
2 0.00/0.06/0.99/0.97
4 0.00/0.00/0.20/0.97
3 g q8h (1/2/3/4 h infusion) 4 0.06/0.96/0.88/0.73
8 0.00/0.00/0.87/0.73
4 g q8h (1/2/3/4 h infusion) 4 0.00/0.00/0.02/0.72
8 0.43/1.00/0.99/0.99
3/6/9/12 g q24h (continuous 
infusion)
4 0.11/0.46/0.99/0.99 
0.02/0.07/0.66/0.99 
0.17/0.99/0.99/0.99 
0.00/0.21/0.99/0.99
